Temsirolimus

Generic Name: Temsirolimus

Brand Names: Torisel

Drug Type: Small Molecule

Chemical Formula: C_₅₆H_₈₇NO_₁₆

CAS Number: 162635-04-3

Unique Ingredient Identifier: 624KN6GM2T

Background: Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.

Indication: For the treatment of renal cell carcinoma (RCC). Also investigated for use/treatment in breast cancer, lymphoma (unspecified), rheumatoid arthritis, and multiple myeloma.

Associated Conditions: Advanced Renal Cell Carcinoma

Associated Therapies: -

Clinical Trials

CCI-779 and EKB-569 in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: pelitinib
Drug: temsirolimus

First Posted Date: 2004-12-08

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 42

Registration Number: NCT00098501

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma

Phase 2

Completed

Conditions: Metastatic Gastrointestinal Carcinoid Tumor
Pulmonary Carcinoid Tumor
Recurrent Gastrointestinal Carcinoid Tumor
Recurrent Islet Cell Carcinoma

Interventions: Drug: temsirolimus
Other: laboratory biomarker analysis

First Posted Date: 2004-10-08

Last Posted Date: 2017-02-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 36

Registration Number: NCT00093782

Locations: 🇨🇦
Princess Margaret Hospital Phase 2 Consortium, Toronto, Ontario, Canada

CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor

Phase 2

Completed

Conditions: Gastrointestinal Stromal Tumor
Recurrent Adult Soft Tissue Sarcoma
Stage I Adult Soft Tissue Sarcoma
Stage II Adult Soft Tissue Sarcoma
Stage III Adult Soft Tissue Sarcoma
Stage IV Adult Soft Tissue Sarcoma

Interventions: Drug: temsirolimus
Other: laboratory biomarker analysis

First Posted Date: 2004-07-12

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 55

Registration Number: NCT00087074

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Phase 2

Terminated

Conditions: Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Adult Hodgkin Lymphoma
Refractory Chronic Lymphocytic Leukemia

Interventions: Drug: temsirolimus
Other: laboratory biomarker analysis

First Posted Date: 2004-07-12

Last Posted Date: 2013-01-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00086840

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase

Phase 2

Completed

Conditions: Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Blastic Phase Chronic Myelogenous Leukemia
de Novo Myelodysplastic Syndromes
Recurrent Adult Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Previously Treated Myelodysplastic Syndromes
Refractory Anemia With Excess Blasts
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Recurrent Adult Acute Lymphoblastic Leukemia
Secondary Myelodysplastic Syndromes

Interventions: Drug: temsirolimus
Other: laboratory biomarker analysis

First Posted Date: 2004-06-11

Last Posted Date: 2013-01-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 74

Registration Number: NCT00084916

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

CCI-779 in Treating Patients With Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2004-03-26

Last Posted Date: 2013-06-24

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00012142

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 2

Completed

Conditions: Refractory Multiple Myeloma
Stage I Multiple Myeloma
Stage II Multiple Myeloma
Stage III Multiple Myeloma

Interventions: Drug: temsirolimus
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2004-03-10

Last Posted Date: 2013-10-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 25

Registration Number: NCT00079456

Locations: 🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States